- Novel Combination Regimens Strengthen and Expand Treatment Paradigm for Genitourinary Cancers.
- Flaherty C, Dorff TB.
- OncLive. 2023 Jan 10.
- Conference news
- Free Full Text
- A polygenic two-hit hypothesis for prostate cancer.
- Houlahan KE, Livingstone J, Fox NS, Kurganovs N, Zhu H, Sietsma Penington J, Jung CH, Yamaguchi TN, Heisler LE, Jovelin R, Costello AJ, Pope BJ, Kishan AU, Corcoran NM, Bristow RG, Waszak SM, Weischenfeldt J, He HH, Hung RJ, Hovens CM, Boutros PC.
- J Natl Cancer Inst. 2023 Jan 5:djad001. doi: 10.1093/jnci/djad001. Epub ahead of print.
- PMID: 36610996
- PubMed abstract
- Source abstract
- Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention.
- Seibert TM, Garraway IP, Plym A, Mahal BA, Giri V, Jacobs MF, Cheng HH, Loeb S, Helfand BT, Eeles RA, Morgan TM.
- Eur Urol. 2023 Jan 4:S0302-2838(22)02870-6. doi: 10.1016/j.eururo.2022.12.021. Epub ahead of print.
- PMID: 36609003
- PubMed abstract
- Source abstract
- Review
- Re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.
- Qi F, Xu Z, Zou Q.
- Eur Urol. 2023 Jan 3:S0302-2838(22)02873-1. doi: 10.1016/j.eururo.2022.12.024. Epub ahead of print.
- PMID: 36604272
- PubMed abstract
- Source abstract
- Letter
•• Original research:
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.
- PMID: 36243543
- PubMed abstract
- Source abstract
•• Reply:
Reply to Feng Qi, Zicheng Xu, and Qing Zou's Letter to the Editor re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.
- PMID: 36623951
- PubMed abstract
- Source abstract
- Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin.
- Miyazawa Y, Shimizu T, Sekine Y, Arai S, Ohtsu A, Fujizuka Y, Nomura M, Koike H, Matsui H, Suzuki K.
- IJU Case Rep. 2022 Oct 9 [eCollection 2023 Jan];6(1):37-40. doi: 10.1002/iju5.12543.
- PMID: 36605692
- PubMed abstract
- Source abstract
- Case report
- Free PMC article
- Free Full Text
•• Letter:
Editorial Comment on "Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin".
- PMID: 36605686
- PubMed abstract
- Free Full Text
- Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer.
- Cheng HH, Sokolova AO, Gulati R, Bowen D, Knerr SA, Klemfuss N, Grivas P, Hsieh A, Lee JK, Schweizer MT, Yezefski T, Zhou A, Yu EY, Nelson PS, Montgomery B.
- JCO Precis Oncol. 2023 Jan;7:e2200104. doi: 10.1200/PO.22.00104.
- PMID: 36623239
- PubMed abstract
- Source abstract
- Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study.
- Brook MN, Ní Raghallaigh H, Govindasami K, Dadaev T, Rageevakumar R, Keating D, Hussain N, Osborne A, Lophatananon A; UKGPCS Collaborators; Muir KR, Kote-Jarai Z, Eeles RA.
- Eur Urol. 2022 Dec 15:S0302-2838(22)02838-X. doi: 10.1016/j.eururo.2022.11.019. Epub ahead of print.
- PMID: 36528478
- PubMed abstract